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Abstract
Truncating mutations in PRNP have been associated with heterogeneous phe-
notypes ranging from chronic diarrhea and neuropathy to dementia, either
rapidly or slowly progressive. We identified novel PRNP stop-codon mutations
(p.Y163X, p.Y169X) in two Italian kindreds. Disease typically presented in the
third or fourth decade with progressive autonomic failure and diarrhea. More-
over, one proband (p.Y163X) developed late cognitive decline, whereas some of
his relatives presented with isolated cognitive and psychiatric symptoms. Our
results strengthen the link between PRNP truncating mutations and systemic
abnormal PrP deposition and support a wider application of PRNP screening
to include unsolved cases of familial autonomic neuropathy.
Introduction
Human prion diseases are neurodegenerative disorders
characterized by tissue accumulation of a misfolded form
(PrPSc) of the cellular prion protein (PrPC). They com-
prise three major phenotypes, namely Creutzfeldt-Jakob
disease (CJD), by far the most common, fatal insomnia
(FI) and Gerstmann-Stra€ussler-Scheinker syndrome
(GSS).1,2 At variance with CJD and FI, GSS manifests a
much slower clinical course and is mainly characterized
by amyloid deposition rather than spongiform change in
the affected brain tissue.2,3 This major phenotypic differ-
ence directly reflects the composition and topology of
PrPSc aggregates. While in CJD and FI PrPSc accumulates
as a full-length or N-terminally truncated fragments
retaining the glycophosphatidylinositol (GPI) membrane
anchor attaching the protein to the cell membrane,4 in
GSS PrPSc mainly deposits in the extracellular space as
unglycosylated anchorless fragments.2,3 GSS was originally
described as a parenchymal brain amyloidosis linked to
missense or insertional mutations in the prion protein
gene (PRNP).2 More recently, however, the discovery of
premature truncating mutations in PRNP has expanded
the phenotypic spectrum of anchorless PrP amyloidosis.
The description of a PRNP stop-codon mutation
(p.Y145X) in a Japanese with dementia and both
ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
777
parenchymal and vascular PrP-amyloid,5,6 was followed
by the findings of similar mutations at codons 160
(p.Q160X),7,8 226 (p.Y226X),9 and 227 (p.Y227X)9 in
patients with progressive dementia and pure PrP-cerebral
amyloid angiopathy (PrP-CAA), GSS or mixed GSS/PrP-
CAA pathology.7,9,10 Most significantly, PRNP truncating
mutations at codons 163 (p.Y163X) and 203 (p.D203X),
have been recently found in patients with chronic diar-
rhea, progressive autonomic failure, and peripheral
polyneuropathy in association with widespread abnormal
PrP deposition in peripheral organs and the CNS.11,12
Based on the multiple organ system PrP deposition and
the amyloid properties of the protein aggregates in the
brain, the term PrP systemic amyloidosis was introduced,
irrespectively of the demonstration of the classical patho-
logical hallmarks of systemic amyloidosis.11,13,14
Here, we describe two Italian families with several
affected members carrying novel truncating mutations in
PRNP associated with progressive autonomic failure and
variable cognitive impairment.
Subjects and Methods
The study was performed according to the Helsinki Dec-
laration and approved by local ethics committee. Written
informed consent was obtained from all subjects.
Genetic Analysis
PRNP (Ref. Seq. NM_000311) open reading frame was
analyzed according to previously described procedures.9
Clinical history
Subjects IV-2A (proband 1) and V-1B in family 1, and
subject III-6 (proband 2) and III-5 in family 2 underwent
a thorough clinical investigation (Fig. 1A–C). For
deceased patients, clinical data were obtained from medi-
cal notes or sought from relatives.
Clinical investigations
Cardiovascular autonomic function was investigated by
means of head-up tilt test (HUTT), Valsalva maneuver, deep
breathing and cold face. Nerve conduction studies were car-
ried out in at least one motor and one sensory nerve and the
sympathetic skin response (SSR) evaluated from the palm of
the hand and the sole of the foot bilaterally.
Cognitive function was explored by the Mini Mental
State Examination and specific neuropsychological batter-
ies for memory, visual-spatial, attention, and executive
performances. Conventional brain MRIs, including
diffusion imaging, and voxel proton MR spectroscopy
were performed according to standard protocols.
Skin studies
Studies of skin innervation were performed in 3-mm
punch biopsies from thigh and calf, according to previ-
ously published procedures.15 For PrP immunohisto-
chemistry, paraffin sections from formalin-fixed tissue
blocks were processed using the monoclonal antibody
3F4, according to published protocols.16
CSF biomarkers
The 14-3-3 protein was measured semi-quantitatively by
immunoblotting, whereas total-tau and neurofilament light
(Nfl-L) proteins were quantitatively analyzed using commer-
cially available kits based on a sandwich ELISA method, as
described.17 Prion RT-QuIC was performed as described.18
Results
PRNP analysis showed a 9-base pair duplicated fragment,
c.478_479insAAGTGTACT, resulting in a p.Y163X stop-
codon mutation in family 1 and a c.507C>A variant
determining a p.Y169X stop-codon mutation associated
with the in-cis missense c.508A>G (p.S170G) in family 2
(Fig. 1D–E). The mutation was in-cis with the valine
allele at codon 129 in family 1 and with the methionine
allele in family 2.
Proband 1 (Fig. 1A) had medical history unremarkable
until the age of 45, when he started complaining of
abdominal pain, chronic diarrhea and progressive weight
loss eventually requiring parenteral nutrition. In the sub-
sequent 10 years, the patient suffered urinary retention
and presented syncopal episodes while standing and dur-
ing urination. Since 63, he also complained of memory
difficulties and confusion. At age of 66, neurologic exami-
nation disclosed short-memory lapses, sluggish reacting
pupils, diffuse brisk deep tendon reflexes, apallesthesia at
the lower limbs, positive Romberg sign, ataxic gait, and
segmental or generalized, both spontaneous and evoked,
myoclonus.
Proband 2 (Fig. 1C) started to complain of abdominal
pain, chronic diarrhea, hyporexia and early satiety at age
of 40. In the next 20 years, she progressively lost about
50 kg and required parenteral nutrition, developed uri-
nary incontinence, bladder and rectal prolapses, and suf-
fered episodes of dizziness and gait unsteadiness, often
immediately after standing. At 61, neurological examina-
tion revealed claw-feet, reduced deep tendon reflexes at
lower limbs, bilateral ptosis, and a mild strabismus.
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Figure 1. Pedigree of family 1 (A,B) and family 2 (C). Arrows point out the probands, while bullets indicate the subjects who underwent genetic
analysis. Although the patient’s ancestors of family 1 were traced back to 1850, there was no common founder for family branches A and B;
however, the two were likely connected because of the restricted geographical residence area (two cities in adjacent provinces with a cumulative
population of ~40,000 people) and the identity of the peculiar genetic mutation. (D and E) Sanger sequencing electropherograms showing the
nucleotide sequence surrounding the two mutations (c.478_479insAAGTGTACT resulting in the p.Y163X mutation on the left; c.507C>A
determining the p.Y169X mutation on the right). (F) A confocal study (magnification 9400) of autonomic patterns of innervation in the proband
1 (upper boxes) and a control subject. The leg autonomic innervation of sweat gland (left) and arrector pilorum muscle (right) were analyzed.
Nerve fibers are marked in red by specific autonomic markers for sweat gland (VIP, vasoactive intestinal peptide) and arrector pilorum muscle
(DbH, dopamine-beta-hydroxylase), whereas the collagen staining is shown in green. The innervation analysis revealed an almost total loss of
cholinergic and noradrenergic fibres in proband 1 compared to the control subject. (G) Immunohistochemical detection of abnormal PrP in
proband 1 (upper box) and in a control subject (magnification 9400). PrP staining with primary antibody 3F4 reveals fine, punctate deposits
(arrowhead) in the upper dermis at the transition to epidermis only in the patient (the box in the lower-right corner shows the PrP deposits at a
higher magnification).
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Clinical findings in other affected members and the
results of instrumental and laboratory investigations of all
subjects are summarized in Tables 1 and 2. Autonomic
tests revealed the impairment of both sympathetic and
parasympathetic autonomic nervous system, fulfilling the
diagnostic criteria for orthostatic hypotension at HUTT
in all tested patients.
Neurophysiologic studies revealed a sensorimotor axonal
polyneuropathy in two out of four tested patients and the
absence of SSR in all. Neuropsychological tests showed, in
proband 1, a selective deficit of visual attention, verbal
memory and logical reasoning at age of 65 progressing to a
multi-domain mild cognitive impairment 1 year later.
Moreover, they revealed a selective deficit of visual memory
or visuo-spatial performances in other tested patients.
Brain MRIs, including proton spectroscopy of the thalamus
and cerebellum (proband 1) or the parieto-occipital white
matter (proband 2), were uninformative in all examined
patients. Skin innervation analysis revealed a severe small
fiber neuropathy with somatic and/or autonomic involve-
ment (Fig. 1F). PrP immunohistochemistry disclosed a fine
punctate PrP staining in the upper dermis next to the tran-
sition to epidermis (Fig. 1G). At variance, skin punch biop-
sies from two patients with probable sCJD carrying MM
and MV at codon 129 showed no abnormal PrP deposits
(data not shown).
The CSF obtained from proband 1 was slightly xan-
tochromic, and showed an increase in total proteins. CSF
biomarker assays revealed a positive 14-3-3 test, markedly
elevated total-tau and Nfl-L levels, and a negative prion
RT-QuIC (Table 2).
Discussion
We have characterized the phenotypic traits of an
inherited prion disease linked to two novel PRNP trun-
cating mutations at codons 163 and 169 affecting sev-
eral members across multiple generations of two Italian
families. The disease showed a typical onset in the third
or fourth decade and a mean disease duration of 15–
20 years. The hallmarks of the clinical phenotype
included a generalized autonomic failure with chronic
diarrhea, weight loss, and neurogenic OH and neuropa-
thy. Beside this typical presentation, however, cognitive
impairment was an early feature in a minority of cases,
in one family.
In genetic prion disease linked to stop-codon PRNP
mutations, the anchorless prion protein may spread
through the interstitial fluids and vascular compart-
ments.13 This was elegantly shown in experimental
studies using transgenic mice expressing a prion protein
lacking the GPI anchor (GPI/), which demonstrated
that the anchorless PrP is secreted from the cells and
accumulates in both brain and peripheral organs after
scrapie infection, assuming the characteristics of a sys-
temic amyloidosis.19
Table 1. Main clinical findings in subjects belonging to families 1 and 2.
Case
Age at
onset Symptom/s at onset
Clinical phenotype
diarrhea OH
urinary
dysfunction
sweating
disorders
sexual
dysfunction
cognitive
impairment
psychiatric
symptoms
axonal
neuropathy
FAMILY 1 (p.Y163X)
Proband
1
45 diarrhea +++ +++ ++ ++ + ++
IV-1A 56 neurogenic bladder + +++ ++ ++
III-1A n.a. urinary retention yes
V-1B 33 diarrhea +++ ++ ++ ++ ++ +/
IV-2B 35 insomnia + + +++ +++
III-2B 30 diarrhea +++
II-2B n.a. n.a. yes
II-3B n.a. psychiatric, cognitive yes yes
FAMILY 2 (p.Y169X)
Proband
2
40 diarrhea +++ +++ ++ +/
III-5 40 diarrhea, neurogenic
bladder, syncope
+++ +++ +++ ++ ++ ++
III-3 40 diarrhea yes yes
I-1 n.a. diarrhea yes
[OH: orthostatic hypotension; source of clinical history: clinical evaluation for proband 1 and 2, V-1B, III-5; medical record for IV-1A, IV-2B, III-2B;
amnestic for III-1A, II-2B, II-3B, III-3, I-1].
+mild; ++moderate; +++severe; n.a.:not available.
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The fact that PRNP truncations in humans result in
heterogeneous phenotypes ranging from dementia to
chronic diarrhea and peripheral neuropathy appears to be
in line with the above observations in animal models,
although the significant phenotypic heterogeneity between
patients carrying different PRNP truncations remains
unexplained.5–12,20
Dementia in patients carrying PRNP stop-codons has
been linked to a GSS-like neuropathologic phenotype with
abundant plaques and neurofibrillary tangles (NFT) and/or
to PrP-CAA.6,7,9,20 Interestingly, widespread PrP plaques
and a substantial amount of tau-related disease in the form
of NFT and neuropil threads also characterized the patients
with the phenotype of chronic diarrhea with autonomic
failure.11 In this context, our observation of a minority of
patients with early cognitive impairment suggests that the
timing of CNS involvement may vary even within subjects
carrying the same PRNP truncating mutation.
The polymorphic codon 129 in the PRNP represents
the strongest susceptibility locus in sporadic and acquired
prion disease and significantly modulates the phenotype
of all forms of prion disease. As in other families with
PRNP stop-codons,6,7,20 both age at onset and clinical
phenotype in our patients were not affected by the geno-
type at codon 129 either in the mutated or wild-type
allele. Moreover, the lack of disease in obligate carriers in
Table 2. Results of laboratory investigations.
Family 1 (p.Y163X) Family 2 (p.Y169X)
Proband 1 Subject V-1B Proband 2 Subject III-5
Cardiovascular reflexes –
HUTT (3rd min): pathological pathological pathological
DSBP, DDBP
(mmHg); DHR (bpm)
50, 30; 8 3, 17; – 54, 38; 4
Valsalva ratio 1.01 – 1.06
Overshoot (mmHg) absent 1.27 absent
Deep breathing: absent arrhythmia – absent arrhythmia
Cold Face (3rd min):
DSBP, DDBP
(mmHg); DHR (bpm)
5, 4; 2 – 23, 15; 2
Electromyography sensorimotor axonal PNP normal normal sensorimotor
axonal PNP
Skin sympathetic
response
absent absent absent absent
Cognitive dysfunction mild global impairment (MMSE 23/30)
with memory and visual attention
dysfunction
globally normal (MMSE 30/
30), but visuo-spatial task
impairment
globally normal (MMSE 26/
30), but visual memory
dysfunction
–
Electroencephalography mild slowing – normal –
Brain MRI1 nonspecific WM hyperintensities normal nonspecific WM
hyperintensities
–
H1-MRS1 normal – normal –
Skin innervation
analysis
autonomic SFN autonomic and somatic SFN autonomic and somatic SFN –
Skin PrP
immunostaining
positive – negative –
Cerebrospinal fluid
analysis
– – –
Total proteins (mg/dL) 215
14.3.3 protein assay positive
Total tau protein
(pg/mL)
17,900
Nf-L (pg/mL) 10,200
Prion RT-QuIC negative
1Performed at the age of 66 in proband 1 and at the age of 60 in proband 2. – , Not done. [HUTT, head-up tilt test; SBP, systolic blood pressure;
DBP, diastolic blood pressure; HR, heart rate (bpm, beats per minute); PNP, polyneuropathy; MMSE, Mini Mental State Examinantion (normal value
>24); WM, white matter; SFN, small fiber neuropathy; H1-MRS, brain single voxel proton magnetic resonance spectroscopy (thalamus and cerebel-
lum were analyzed in proband 1, parietal and occipital white matter in proband 2); Nf-L, neurofilament light chain protein; prion RT-QuIC, detec-
tion of prion seeding activity using real-time quaking induced conversion assay].
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family 2 strongly suggests that the penetrance of the trun-
cating PRNP mutations may be incomplete, as previously
reported in a family carrying the PRNP p.Y160X.20
The possibility of a prion-related systemic amyloidosis
in patients presenting with slowly progressive symptoms
and signs of autonomic and sensory neuropathy is still
poorly recognized. Indeed, the diagnostic delay in our
patients was remarkable. Most patients are initially
referred to a gastroenterologist, and unhelpful tests and
misdiagnoses are common, especially in the early clinical
stages. Thus, PRNP genetic testing should be recom-
mended in all patients presenting with insidious general-
ized autonomic failure, and a positive family history of
autonomic failure and/or cognitive decline. Moreover,
the significance and potential diagnostic role of the
unexpected increase in CSF neurodegenerative biomark-
ers we documented in a single patient should be
addressed.
In conclusion, based on clinical findings (i.e., periph-
eral autonomic neuropathy) and the demonstration of
PrP deposition in the skin, the present data strengthen
the link between PRNP truncating mutations and sys-
temic PrP amyloidosis. They also consolidate current
knowledge on the clinical expression of these mutations,
confirming that dementia and autonomic failure may
coexist in the same family and support a wider applica-
tion of PRNP screening to include unsolved cases of
familial autonomic polyneuropathy.
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